NCT06161233Completed
Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy
Source: ClinicalTrials.gov · Last updated 8 Mar 2024
Brief summary (registry, in English)
The purpose of the CAPABLE study is to compare health-related quality of life in renal cell carcinoma patients who use or do not use a mobile-based application to monitor adverse events for cancer treatment at home. As secondary objectives, the study investigates the usability of the system and its generalizability to other cancer types
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 56 (actual)
- First submitted
- 30 Nov 2023
- Start date
- 16 May 2023
- Primary completion date
- 31 Jan 2024
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Diseases
- Head and neck cancer, Thyroid cancer, Kidney cancer, Lung cancer, Gastric and esophageal cancer, Ovarian cancer
- NCT number
- NCT06161233
What you commit to
- Study type: Interventional
- Participants enrolled: 56
- From 16 May 2023 to the primary completion date, 31 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Recruitment and consent denial
- Not able of understanding and complying with the protocol requirements (including basic technological abilities)
- Given the fact that each subject involved in the clinical study must be able to understand and sign the informed consent presented by the researcher, lack of this capability represents a specific exclusion criterion in the study protocol.
Who the study is looking for
- Adults (age \>=18 years)
- Sufficient understanding of the Italian language
- Patients or their caregiver (upon patient's consent) can use a smartphone
- Histologically or cytologically confirmed diagnosis of RCC, lung, breast, thyroid o head and neck cancer
- Candidate to systemic treatment (targeted agents, immune checkpoint inhibitors, or a combination of the two)
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at the start of the treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istituti Clinici Scientifici Maugeri Spa SB Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.